Raras
Buscar doenças, sintomas, genes...
Câncer de ovário raro
ORPHA:213500CID-10 · C56CID-11 · 2C73OMIM 167000DOENÇA RARA

É um câncer que afeta o ovário, podendo ter começado nele (primário) ou se espalhado de outro lugar (metastático). A maioria dos cânceres primários de ovário são carcinomas (tipos comuns incluem o seroso, mucinoso ou endometrióide) ou tumores malignos de células germinativas (que se originam das células que formam os óvulos). Já os cânceres que se espalham para o ovário (metastáticos) podem ser carcinomas, linfomas (câncer do sistema linfático) e melanomas (um tipo de câncer de pele).

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

É um câncer que afeta o ovário, podendo ter começado nele (primário) ou se espalhado de outro lugar (metastático). A maioria dos cânceres primários de ovário são carcinomas (tipos comuns incluem o seroso, mucinoso ou endometrióide) ou tumores malignos de células germinativas (que se originam das células que formam os óvulos). Já os cânceres que se espalham para o ovário (metastáticos) podem ser carcinomas, linfomas (câncer do sistema linfático) e melanomas (um tipo de câncer de pele).

Publicações científicas
40 artigos
Último publicado: 2026 Feb 16
Medicamentos
6 registrados
GEMCITABINE HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, RUCAPARIB CAMSYLATE

Tem tratamento?

6 medicamentos registrados
Ver detalhes, fases e interações →
GEMCITABINE HYDROCHLORIDEDOXORUBICIN HYDROCHLORIDERUCAPARIB CAMSYLATENIRAPARIB TOSYLATE MONOHYDRATEOLAPARIBBEVACIZUMAB

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-5 / 10 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
49.0
Europe
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C56
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
3 sintomas
🫃
Digestivo
2 sintomas
🧬
Pele e cabelo
1 sintomas
👂
Ouvidos
1 sintomas

+ 11 sintomas em outras categorias

Características mais comuns

Anormalidade do metabolismo/homeostase
Calcificação gonadal
Genitália ambígua
Hirsutismo
Distensão abdominal
Disgenesia gonadal com aparência feminina, masculina
18sintomas
Sem dados (18)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 18 características clínicas mais associadas, ordenadas por frequência.

Anormalidade do metabolismo/homeostaseAbnormality of metabolism/homeostasis
Calcificação gonadalGonadal calcification
Genitália ambíguaAmbiguous genitalia
HirsutismoHirsutism
Distensão abdominalAbdominal distention

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico40PubMed
Últimos 10 anos41publicações
Pico20249 papers
Linha do tempo
2026Hoje · 2026🧪 1989Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

12 genes identificados com associação a esta condição.

CTNNB1Catenin beta-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Key downstream component of the canonical Wnt signaling pathway (PubMed:17524503, PubMed:18077326, PubMed:18086858, PubMed:18957423, PubMed:21262353, PubMed:22155184, PubMed:22647378, PubMed:22699938). In the absence of Wnt, forms a complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B that promotes phosphorylation on N-terminal Ser and Thr residues and ubiquitination of CTNNB1 via BTRC and its subsequent degradation by the proteasome (PubMed:17524503, PubMed:18077326, PubMed:18086858, PubMed:189574

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, cytoskeletonCell junction, adherens junctionCell junctionCell membraneCytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, spindle poleSynapseCytoplasm, cytoskeleton, cilium basal body

VIAS BIOLÓGICAS (10)
Formation of the nephric ductSpecification of the neural plate borderSynthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)TCF dependent signaling in response to WNTTranscriptional Regulation by VENTX
MECANISMO DE DOENÇA

Colorectal cancer

A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
297.5 TPM
Cervix Ectocervix
257.8 TPM
Artéria tibial
233.5 TPM
Ovário
201.9 TPM
Cérebro - Hemisfério cerebelar
201.3 TPM
OUTRAS DOENÇAS (17)
hepatocellular carcinomasevere intellectual disability-progressive spastic diplegia syndromeovarian cancerpilomatrixoma
HGNC:2514UniProt:P35222
OPCMLOpioid-binding protein/cell adhesion moleculeDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Binds opioids in the presence of acidic lipids; probably involved in cell contact

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Post-translational modification: synthesis of GPI-anchored proteins
MECANISMO DE DOENÇA

Ovarian cancer

The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
75.5 TPM
Cerebelo
60.1 TPM
Brain Frontal Cortex BA9
39.2 TPM
Córtex cerebral
24.7 TPM
Brain Anterior cingulate cortex BA24
18.9 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
ovarian cancer
HGNC:HGNC:8143UniProt:Q14982
INHBAInhibin beta A chainCandidate gene tested inAltamente restrito
FUNÇÃO

Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition Activin A is a homodimer of INHBA that plays a role in several essential biological processes including embryonic development, stem cell maintenance and dif

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (5)
Signaling by ActivinAntagonism of Activin by FollistatinGlycoprotein hormonesSignaling by BMPTGFBR3 regulates activin signaling
EXPRESSÃO TECIDUAL(Tecido-específico)
Artéria tibial
21.2 TPM
Aorta
19.3 TPM
Artéria coronária
17.7 TPM
Fibroblastos
17.1 TPM
Pulmão
8.3 TPM
OUTRAS DOENÇAS (1)
ovarian adenocarcinoma
HGNC:6066UniProt:P08476
FOXL2Forkhead box protein L2Candidate gene tested inTolerante
FUNÇÃO

Transcriptional regulator. Critical factor essential for ovary differentiation and maintenance, and repression of the genetic program for somatic testis determination. Prevents trans-differentiation of ovary to testis through transcriptional repression of the Sertoli cell-promoting gene SOX9 (By similarity). Has apoptotic activity in ovarian cells. Suppresses ESR1-mediated transcription of PTGS2/COX2 stimulated by tamoxifen (By similarity). Is a regulator of CYP19 expression (By similarity). Par

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (1)
SUMOylation of transcription factors
MECANISMO DE DOENÇA

Blepharophimosis, ptosis, and epicanthus inversus syndrome

A disorder characterized by eyelid dysplasia, small palpebral fissures, drooping eyelids and a skin fold curving in the mediolateral direction, inferior to the inner canthus. In type I BPSE (BPES1) eyelid abnormalities are associated with female infertility. Affected females show an ovarian deficit due to primary amenorrhea or to premature ovarian failure (POF). In type II BPSE (BPES2) affected individuals show only the eyelid defects.

EXPRESSÃO TECIDUAL(Tecido-específico)
Ovário
102.0 TPM
Cervix Endocervix
31.4 TPM
Cervix Ectocervix
26.6 TPM
Fallopian Tube
25.6 TPM
Pituitária
19.0 TPM
OUTRAS DOENÇAS (6)
premature ovarian failure 3blepharophimosis, ptosis, and epicanthus inversus syndromemaligant granulosa cell tumor of ovaryblepharophimosis-ptosis-epicanthus inversus syndrome type 1
HGNC:1092UniProt:P58012
PRKNE3 ubiquitin-protein ligase parkinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins (PubMed:10888878, PubMed:10973942, PubMed:11431533, PubMed:12150907, PubMed:12628165, PubMed:15105460, PubMed:16135753, PubMed:21376232, PubMed:21532592, PubMed:22396657, PubMed:23620051, PubMed:23754282, PubMed:24660806, PubMed:24751536, PubMed:29311685, PubMed:32047033). Substrates include SYT11 and VDAC1 (PubMed:29311685, PubMed:32047033). Other substra

LOCALIZAÇÃO

Cytoplasm, cytosolNucleusEndoplasmic reticulumMitochondrionMitochondrion outer membraneCell projection, neuron projectionPostsynaptic densityPresynapse

VIAS BIOLÓGICAS (5)
AggrephagyPINK1-PRKN Mediated MitophagyAntigen processing: Ubiquitination & Proteasome degradationAmyloid fiber formationJosephin domain DUBs
MECANISMO DE DOENÇA

Parkinson disease

A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

OUTRAS DOENÇAS (4)
ovarian cancerautosomal recessive juvenile Parkinson disease 2lung canceryoung-onset Parkinson disease
HGNC:8607UniProt:O60260
PIK3CAPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides (PubMed:15135396, PubMed:23936502, PubMed:28676499). Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3) (PubMed:15135396, PubMed:28676499). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1,

LOCALIZAÇÃO

VIAS BIOLÓGICAS (10)
Signaling by LTK in cancerNephrin family interactionsIRS-mediated signallingTie2 SignalingDAP12 signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
23.2 TPM
Linfócitos
22.4 TPM
Nervo tibial
21.4 TPM
Tecido adiposo
20.5 TPM
Fibroblastos
20.5 TPM
OUTRAS DOENÇAS (28)
seborrheic keratosismegalodactylyovarian cancerhepatocellular carcinoma
HGNC:8975UniProt:P42336
AKT1RAC-alpha serine/threonine-protein kinaseDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis (PubMed:11882383, PubMed:15526160, PubMed:15861136, PubMed:21432781, PubMed:21620960, PubMed:31204173). This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates (PubMed:11882383, PubMed:15526160, PubMed:21432781, PubMed:21620960, PubMe

LOCALIZAÇÃO

CytoplasmNucleusCell membraneMitochondrion intermembrane space

VIAS BIOLÓGICAS (7)
CD28 dependent PI3K/Akt signalingVEGFR2 mediated vascular permeabilityPIP3 activates AKT signalingNegative regulation of the PI3K/AKT networkG beta:gamma signalling through PI3Kgamma
MECANISMO DE DOENÇA

Breast cancer

A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

OUTRAS DOENÇAS (7)
ovarian cancerProteus syndromehereditary breast carcinomacolorectal cancer
HGNC:391UniProt:P31749
CDH1Cadherin-1Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Cadherins are calcium-dependent cell adhesion proteins (PubMed:11976333). They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells (PubMed:11976333). Promotes organization of radial actin fiber structure and cellular response to contractile forces, via its interaction with AMOTL2 whi

LOCALIZAÇÃO

Cell junction, adherens junctionCell membraneEndosomeGolgi apparatus, trans-Golgi networkCytoplasmCell junction, desmosome

VIAS BIOLÓGICAS (1)
Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
MECANISMO DE DOENÇA

Diffuse gastric and lobular breast cancer syndrome

A cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. In addition to gastric cancer, most female mutation carriers develop lobular carcinoma of the breast.

OUTRAS DOENÇAS (9)
CDH1-related diffuse gastric and lobular breast cancer syndromeovarian cancerblepharocheilodontic syndrome 1endometrial cancer
HGNC:1748UniProt:P12830
BMP15Bone morphogenetic protein 15Candidate gene tested inTolerante
FUNÇÃO

May be involved in follicular development. Oocyte-specific growth/differentiation factor that stimulates folliculogenesis and granulosa cell (GC) growth

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Ovarian dysgenesis 2

A disorder characterized by lack of spontaneous pubertal development, primary amenorrhea, uterine hypoplasia, and hypergonadotropic hypogonadism as a result of streak gonads.

OUTRAS DOENÇAS (3)
ovarian dysgenesis 2immature ovarian teratoma46 XX gonadal dysgenesis
HGNC:1068UniProt:O95972
DICER1Endoribonuclease DicerCandidate gene tested inAltamente restrito
FUNÇÃO

Double-stranded RNA (dsRNA) endoribonuclease playing a central role in short dsRNA-mediated post-transcriptional gene silencing. Cleaves naturally occurring long dsRNAs and short hairpin pre-microRNAs (miRNA) into fragments of twenty-one to twenty-three nucleotides with 3' overhang of two nucleotides, producing respectively short interfering RNAs (siRNA) and mature microRNAs. SiRNAs and miRNAs serve as guide to direct the RNA-induced silencing complex (RISC) to complementary RNAs to degrade them

LOCALIZAÇÃO

CytoplasmCytoplasm, perinuclear region

VIAS BIOLÓGICAS (5)
MicroRNA (miRNA) biogenesisSmall interfering RNA (siRNA) biogenesistRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesisM-decay: degradation of maternal mRNAs by maternally stored factorsRegulation of MITF-M-dependent genes involved in apoptosis
MECANISMO DE DOENÇA

Pleuropulmonary blastoma

A rare pediatric intrathoracic neoplasm. The tumor arises from the lung, pleura, or both, and appears to be purely mesenchymal in phenotype. It lacks malignant epithelial elements, a feature that distinguishes it from the classic adult-type pulmonary blastoma. It arises during fetal lung development and is often part of an inherited cancer syndrome. The tumor contain both epithelial and mesenchymal cells. Early in tumorigenesis, cysts form in lung airspaces, and these cysts are lined with benign-appearing epithelium. Mesenchymal cells susceptible to malignant transformation reside within the cyst walls and form a dense layer beneath the epithelial lining. In a subset of patients, overgrowth of the mesenchymal cells produces a sarcoma, a transition that is associated with a poorer prognosis. Some patients have multilocular cystic nephroma, a benign kidney tumor.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
46.1 TPM
Tireoide
31.6 TPM
Cervix Endocervix
31.4 TPM
Útero
31.2 TPM
Ovário
30.2 TPM
OUTRAS DOENÇAS (10)
pleuropulmonary blastomaglobal developmental delay - lung cysts - overgrowth - Wilms tumor syndromegoiter, multinodular 1, with or without Sertoli-Leydig cell tumorsrhabdomyosarcoma, embryonal, 2
HGNC:17098UniProt:Q9UPY3
ERBB2Receptor tyrosine-protein kinase erbB-2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell memb

LOCALIZAÇÃO

Cell membraneCell projection, ruffle membraneEarly endosomeCytoplasm, perinuclear regionNucleusCytoplasm

VIAS BIOLÓGICAS (9)
Signaling by ERBB2Constitutive Signaling by Overexpressed ERBB2Drug-mediated inhibition of ERBB2 signalingDownregulation of ERBB2 signalingSema4D induced cell migration and growth-cone collapse
MECANISMO DE DOENÇA

Glioma

Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
130.1 TPM
Skin Sun Exposed Lower leg
118.3 TPM
Esôfago - Mucosa
113.1 TPM
Skin Not Sun Exposed Suprapubic
110.9 TPM
Tireoide
99.3 TPM
OUTRAS DOENÇAS (9)
gastric cancervisceral neuropathy, familial, 2, autosomal recessiveglioma susceptibility 1lung cancer
HGNC:3430UniProt:P04626
SMARCA4SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4Candidate gene tested inAltamente restrito
FUNÇÃO

ATPase involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner (PubMed:15075294, PubMed:29374058, PubMed:30339381, PubMed:32459350). Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter ac

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (10)
Formation of the beta-catenin:TCF transactivating complexNegative Regulation of CDH1 Gene TranscriptionRUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not knownRMTs methylate histone argininesFormation of neuronal progenitor and neuronal BAF (npBAF and nBAF)
MECANISMO DE DOENÇA

Rhabdoid tumor predisposition syndrome 2

A familial cancer syndrome predisposing to renal or extrarenal malignant rhabdoid tumors and to a variety of tumors of the central nervous system, including choroid plexus carcinoma, medulloblastoma, and central primitive neuroectodermal tumors. Rhabdoid tumors are the most aggressive and lethal malignancies occurring in early childhood.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
81.7 TPM
Cérebro - Hemisfério cerebelar
65.7 TPM
Cerebelo
62.6 TPM
Linfócitos
61.0 TPM
Esôfago - Mucosa
57.8 TPM
OUTRAS DOENÇAS (7)
intellectual disability, autosomal dominant 16otosclerosis 12Coffin-Siris syndromeovarian small cell carcinoma
HGNC:11100UniProt:P51532

Medicamentos e terapias

GEMCITABINE HYDROCHLORIDEPhase 4

Mecanismo: DNA polymerase (alpha/delta/epsilon) inhibitor

DOXORUBICIN HYDROCHLORIDEPhase 4

Mecanismo: DNA topoisomerase II alpha inhibitor

RUCAPARIB CAMSYLATEPhase 4

Mecanismo: PARP 1, 2 and 3 inhibitor

NIRAPARIB TOSYLATE MONOHYDRATEPhase 4

Mecanismo: Poly [ADP-ribose] polymerase 2 inhibitor

OLAPARIBPhase 4

Mecanismo: PARP 1, 2 and 3 inhibitor

BEVACIZUMABPhase 4

Mecanismo: Vascular endothelial growth factor A inhibitor

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

2,114 variantes patogênicas registradas no ClinVar.

🧬 SMARCA4: NM_003072.5(SMARCA4):c.1849del (p.Pro616_Val617insTer) ()
🧬 SMARCA4: NM_003072.5(SMARCA4):c.4318C>T (p.Gln1440Ter) ()
🧬 SMARCA4: NM_003072.5(SMARCA4):c.1761+2T>G ()
🧬 SMARCA4: NM_003072.5(SMARCA4):c.768del (p.Asn259fs) ()
🧬 SMARCA4: NM_003072.5(SMARCA4):c.3229dup (p.Arg1077fs) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

154 vias biológicas associadas aos genes desta condição.

Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade TCF dependent signaling in response to WNT Formation of the beta-catenin:TCF transactivating complex LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Apoptotic cleavage of cell adhesion proteins Deactivation of the beta-catenin transactivating complex Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) Ca2+ pathway Adherens junctions interactions Binding of TCF/LEF:CTNNB1 to target gene promoters Disassembly of the destruction complex and recruitment of AXIN to the membrane VEGFR2 mediated vascular permeability Myogenesis Signaling by GSK3beta mutants CTNNB1 S33 mutants aren't phosphorylated CTNNB1 S37 mutants aren't phosphorylated CTNNB1 S45 mutants aren't phosphorylated CTNNB1 T41 mutants aren't phosphorylated RHO GTPases activate IQGAPs Transcriptional Regulation by VENTX InlA-mediated entry of Listeria monocytogenes into host cells RUNX3 regulates WNT signaling Cardiogenesis Germ layer formation at gastrulation Regulation of CDH11 function Regulation of CDH19 Expression and Function Regulation of CDH1 Function Degradation of CDH1 Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Post-translational modification: synthesis of GPI-anchored proteins Signaling by Activin Signaling by BMP Glycoprotein hormones Antagonism of Activin by Follistatin TGFBR3 regulates activin signaling SUMOylation of transcription factors PINK1-PRKN Mediated Mitophagy Regulation of necroptotic cell death Josephin domain DUBs Aggrephagy Amyloid fiber formation Antigen processing: Ubiquitination & Proteasome degradation PI3K Cascade IRS-mediated signalling GPVI-mediated activation cascade Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K events in ERBB4 signaling PIP3 activates AKT signaling Signaling by SCF-KIT Synthesis of PIPs at the plasma membrane GAB1 signalosome Signaling by cytosolic FGFR1 fusion mutants Downstream signal transduction PI3K events in ERBB2 signaling PI3K/AKT activation Signaling by ALK Downstream TCR signaling Role of phospholipids in phagocytosis Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions CD28 dependent PI3K/Akt signaling G alpha (q) signalling events VEGFA-VEGFR2 Pathway Interleukin-3, Interleukin-5 and GM-CSF signaling Constitutive Signaling by EGFRvIII PI-3K cascade:FGFR1 PI-3K cascade:FGFR2 PI-3K cascade:FGFR3 PI-3K cascade:FGFR4 Activation of BAD and translocation to mitochondria Downregulation of ERBB2:ERBB3 signaling Translocation of SLC2A4 (GLUT4) to the plasma membrane Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation MTOR signalling AKT phosphorylates targets in the cytosol AKT phosphorylates targets in the nucleus Negative regulation of the PI3K/AKT network eNOS activation AKT-mediated inactivation of FOXO1A Integrin signaling Co-inhibition by CTLA4 G beta:gamma signalling through PI3Kgamma Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Interleukin-4 and Interleukin-13 signaling Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 RAB GEFs exchange GTP for GDP on RABs Degradation of the extracellular matrix Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Integrin cell surface interactions Regulation of CDH1 mRNA translation by microRNAs Formation of definitive endoderm Transcriptional and post-translational regulation of MITF-M expression and activity Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Myoepithelial Cells Developmental Lineage of Mammary Stem Cells Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation MicroRNA (miRNA) biogenesis Small interfering RNA (siRNA) biogenesis tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis M-decay: degradation of maternal mRNAs by maternally stored factors Regulation of MITF-M-dependent genes involved in apoptosis Signaling by ERBB2 SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling GRB7 events in ERBB2 signaling GRB2 events in ERBB2 signaling Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Interleukin-7 signaling RMTs methylate histone arginines Chromatin modifying enzymes RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known EGR2 and SOX10-mediated initiation of Schwann cell myelination Negative Regulation of CDH1 Gene Transcription Regulation of MITF-M-dependent genes involved in pigmentation Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) Formation of the canonical BAF (cBAF) complex Formation of the polybromo-BAF (pBAF) complex Formation of the embryonic stem cell BAF (esBAF) complex Formation of the non-canonical BAF (ncBAF) complex Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado6
Medicamentos catalogadosEnsaios clínicos· 6 medicamentos · 0 ensaios
✓ Aprovados — podem ser usados hoje
GEMCITABINE HYDROCHLORIDEDOXORUBICIN HYDROCHLORIDERUCAPARIB CAMSYLATENIRAPARIB TOSYLATE MONOHYDRATEOLAPARIBBEVACIZUMAB
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Câncer de ovário raro

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
39 papers (10 anos)
#1

Endometrial pathology and surgical extent in ovarian adult granulosa cell tumor: associations with stage and survival.

American journal of obstetrics and gynecology2026 Feb 16

Este estudo revelou que a presença de sangramento uterino anormal ou patologias endometriais (hiperplasia ou câncer) está associada a um estágio mais baixo do tumor de células da granulosa (TCG) ovariano, sugerindo uma detecção mais precoce que não afeta negativamente a sobrevida geral das pacientes. Para médicos e pacientes, o estadiamento cirúrgico completo não demonstrou melhorar a sobrevida livre de progressão, embora estágios mais avançados (IC ou superior) continuem associados a um maior risco de recorrência.

🇧🇷 traduzido
#2

Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type.

iScience2025 Feb 21

O carcinoma de pequenas células do ovário, tipo hipercalcêmico (SCCOHT), é um câncer raro e agressivo que afeta mulheres jovens. Este estudo aprofunda a compreensão de sua biologia, mostrando que a perda de proteínas SMARCA4/SMARCA2 altera "super-enhancers" que regulam genes de desenvolvimento, como os do sistema nervoso. Crucialmente, a pesquisa demonstrou que o composto triptolida (e seu pró-fármaco minnelide) é altamente eficaz contra células de SCCOHT e inibe o crescimento tumoral em modelos pré-clínicos, oferecendo uma promissora nova abordagem terapêutica ao atuar sobre esses "super-enhancers".

🇧🇷 traduzido
#3

Experiences of radiotherapy for treatment of Granulosa Cell Tumor of the ovary: insights from the GCT-survivor sisters.

Gynecologic oncology2025 Dec

O tratamento ideal para o Tumor de Células da Granulosa (TCG) ainda é incerto, e a radioterapia, embora não seja comum, é utilizada para a doença recorrente, com sua aplicação variando significativamente entre diferentes países. A maioria das pacientes que receberam radioterapia relata experiências positivas, como eficácia no tratamento e melhoria na qualidade de vida, apesar de algumas terem sofrido efeitos colaterais severos. Isso ressalta a importância de mais pesquisas para estabelecer diretrizes claras sobre o momento e a forma mais eficaz de usar a radioterapia no manejo do TCG.

🇧🇷 traduzido
#4

Multiplexed Imaging Mass Cytometry Reveals Tumor-immune Microenvironment-dependent Hormone Receptor Expression in Adult-Type Ovarian Granulosa Cell Tumors.

Cancer research communications2025 Oct 01

Este estudo inovador sobre os raros tumores de células da granulosa do ovário (AGCT), com poucas opções de tratamento para casos recorrentes, revelou a existência de dois subtipos distintos: AGCT-1 e AGCT-2. Esses subtipos diferem significativamente em sua composição celular, atividade imune (com mais macrófagos em tumores recorrentes) e sinais hormonais, como a expressão do receptor de progesterona. Essa nova classificação é crucial para guiar abordagens terapêuticas mais personalizadas e eficazes, oferecendo novas esperanças para pacientes com esta malignidade rara.

🇧🇷 traduzido
#5

The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study.

Gynecologic oncology2025 Nov

Este estudo sobre o câncer de ovário de células claras avançado (OCCC) revela um prognóstico desfavorável, com a quimioterapia neoadjuvante (NACT) não apresentando melhorias significativas na ressecabilidade ou sobrevida em comparação com a cirurgia citorredutora primária (PCS). No entanto, o esforço cirúrgico máximo para atingir doença residual mínima (RD ≤10mm ou idealmente RD0) foi crucial, associando-se a melhores resultados de sobrevida e sublinhando a importância da qualidade da citorredução para esses pacientes.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMC8 artigos no totalmostrando 41

2026

Endometrial pathology and surgical extent in ovarian adult granulosa cell tumor: associations with stage and survival.

American journal of obstetrics and gynecology
2025

Experiences of radiotherapy for treatment of Granulosa Cell Tumor of the ovary: insights from the GCT-survivor sisters.

Gynecologic oncology
2025

Multiplexed Imaging Mass Cytometry Reveals Tumor-immune Microenvironment-dependent Hormone Receptor Expression in Adult-Type Ovarian Granulosa Cell Tumors.

Cancer research communications
2025

The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study.

Gynecologic oncology
2025

Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.

Cancer research
2025

Targeting Mediator Kinase Cyclin-Dependent Kinases 8/19 Potentiates Chemotherapeutic Responses, Reverses Tumor Growth, and Prolongs Survival from Ovarian Clear Cell Carcinoma.

Cancers
2025

Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
2025

Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type.

iScience
2025

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti-tumoral compounds.

Molecular oncology
2024

GW0742 as a Potential TRα and TRβ Antagonist Reduces the Viability and Metabolic Activity of an Adult Granulosa Tumour Cell Line and Simultaneously Upregulates TRβ Expression.

Cancers
2024

Epigenetic Therapy in a Rare Ovarian Cancer - A Double-Edged Sword.

The New England journal of medicine
2024

Single-molecule epiallelic profiling of DNA derived from routinely collected Pap specimens for noninvasive detection of ovarian cancer.

Clinical and translational medicine
2024

Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).

Pleura and peritoneum
2024

A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
2024

Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand.

The Australian &amp; New Zealand journal of obstetrics &amp; gynaecology
2024

Successful treatment of stage IVB ovarian carcinosarcoma with PARP Inhibitor: A case report.

Gynecologic oncology reports
2024

Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.

Histopathology
2024

Top advances of the year: Ovarian cancer.

Cancer
2023

Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.

Gynecologic oncology
2023

Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome.

Gynecologic oncology
2023

How social media can help to understand treatment experiences of survivors of rare cancers: Findings from the Granulosa Cell Tumor Survivor Sisters Facebook group member survey.

Cancer
2023

A Rare Case of Ruptured Malignant Ovarian Brenner Tumor.

The American journal of case reports
2022

Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Anticancer research
2022

Rare Ovarian Cancer's First Positive Trial.

Cancer discovery
2022

Non-Gestational Ovarian Choriocarcinoma: A Rare Ovarian Cancer Subtype.

Diagnostics (Basel, Switzerland)
2022

Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus.

Gynecologic oncology reports
2022

DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.

Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
2021

Low-Grade Ovarian Serous Adenocarcinoma with Lymph Node Metastasis in Neck.

Diagnostics (Basel, Switzerland)
2021

Immunotherapy in rare ovarian cancer.

Current opinion in oncology
2021

Familial Occurrence of Adult Granulosa Cell Tumors: Analysis of Whole-Genome Germline Variants.

Cancers
2021

Malignant struma ovarii: surgical, histopathological and survival outcomes for thyroid-type carcinoma of struma ovarii with recommendations for standardising multi-modal management. A retrospective case series sharing the experience of a single institution over 10 years.

Archives of gynecology and obstetrics
2020

Confronting a rare ovarian cancer during lockdown.

The Lancet. Respiratory medicine
2020

MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2020

Natural killer cell impairment in ovarian clear cell carcinoma.

Journal of leukocyte biology
2020

Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.

Clinical cancer research : an official journal of the American Association for Cancer Research
2020

Low-grade serous ovarian cancer: State of the science.

Gynecologic oncology
2019

Management of Rare Ovarian Cancer Histologies.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2019

Metastasis of ovarian cancer to the bile duct: a case report.

Surgical case reports
2019

Ovarian Clear Cell Carcinoma in Cowden Syndrome.

Journal of the National Comprehensive Cancer Network : JNCCN
2018

Identification of Driver Mutations in Rare Cancers: The Role of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT).

Methods in molecular biology (Clifton, N.J.)
2017

Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma.

Frontiers in oncology

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Câncer de ovário raro.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Câncer de ovário raro

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Endometrial pathology and surgical extent in ovarian adult granulosa cell tumor: associations with stage and survival.
    American journal of obstetrics and gynecology· 2026· PMID 41707897mais citado
  2. Super-enhancers and efficacy of triptolide in small cell carcinoma of the ovary hypercalcemic type.
    iScience· 2025· PMID 39906560mais citado
  3. Experiences of radiotherapy for treatment of Granulosa Cell Tumor of the ovary: insights from the GCT-survivor sisters.
    Gynecologic oncology· 2025· PMID 41175448mais citado
  4. Multiplexed Imaging Mass Cytometry Reveals Tumor-immune Microenvironment-dependent Hormone Receptor Expression in Adult-Type Ovarian Granulosa Cell Tumors.
    Cancer research communications· 2025· PMID 41042551mais citado
  5. The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study.
    Gynecologic oncology· 2025· PMID 41004925mais citado
  6. Loss of SMARCA4 Leads to Intron Retention and Generation of Tumor-Associated Antigens in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.
    Cancer Res· 2025· PMID 40407709recente
  7. Targeting Mediator Kinase Cyclin-Dependent Kinases 8/19 Potentiates Chemotherapeutic Responses, Reverses Tumor Growth, and Prolongs Survival from Ovarian Clear Cell Carcinoma.
    Cancers (Basel)· 2025· PMID 40149277recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:213500(Orphanet)
  2. OMIM OMIM:167000(OMIM)
  3. MONDO:0008170(MONDO)
  4. GARD:7295(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q172341(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Câncer de ovário raro
Compêndio · Raras BR

Câncer de ovário raro

ORPHA:213500 · MONDO:0008170
Prevalência
1-5 / 10 000
CID-10
C56 · Neoplasia maligna do ovário
CID-11
Medicamentos
6 registrados
Prevalência
49.0 (Europe)
MedGen
UMLS
C3810371
Repurposing
10 candidatos
altretamineDNA synthesis inhibitor
carboplatinDNA alkylating agent|DNA inhibitor
cisplatinDNA alkylating agent|DNA synthesis inhibitor
+7 outros
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades